Research study for adults with Progressive Supranuclear Palsy (PSP)

IRB/UVA Tracking #
20025
Principal Investigator
Barrett Matthew,
Contact First Name

Katie

Contact Last Name

Sullivan

Contact Email
Contact Phone
Official Trial Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy
Study Description

The Department of Neurology seeks adults, age 41 to 86 years, with Progressive Supranuclear Palsy (PSP) for a research study. Although some medications may help relieve symptoms associated with this disease, none have been proven to slow or halt the disease itself. The purpose of the study is to find out if a new investigational study drug can slow the progression of the disease.

The main trial lasts just over a year. It is divided into a 6-week screening period and a 52-week treatment period with study medication or placebo. Participants will visit the clinical research unit approximately every 4 weeks throughout the trial to have their health monitored. Once this portion of the trial concludes, there will also be an opportunity to participate in an open-label dosing period.

You may be eligible for this study if you can walk independently or with assistance for at least 10 steps with or without a walker. Each participant must have a caregiver who will accompany him or her to all study visits.

Screening includes assessments to determine eligibility and an optional lumbar puncture. Once enrolled, study involves an MRI, blood draws, memory testing and intravenous drug infusion.
All trial-related medications, tests and assessments will be given to participants at no cost. Reimbursement for travel and other trial-related expenses may be available.

Compensation

none